search
Back to results

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Primary Purpose

Hypertension, Plasma Renin Activity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Hydrochlorothiazide
Lisinopril
Amlodipine
metoprolol
lisinopril/hydrochlorothiazide
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg
  • Not currently taking BP-lowering medication
  • Clinician recommends pharmacologic treatment
  • Willing to make necessary study visits
  • Able to be contacted by phone
  • Has a primary care clinician
  • At least 18 years old

Exclusion Criteria:

  • Known secondary cause of hypertension
  • Pregnancy
  • Known diabetes, coronary artery disease or renal disease
  • Known sulfonamide allergy or history of gout
  • Participant's clinician recommends he/she not enroll
  • Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit
  • Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg
  • Resting heart rate < 55 beats per minute

Sites / Locations

  • UNC Chapel Hill

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PRA-guided therapy

Fixed-dose combination treatment-guided therapy

Arm Description

Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.

Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.

Outcomes

Primary Outcome Measures

Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (<140mmHG systolic and <90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.

Secondary Outcome Measures

Full Information

First Posted
July 31, 2012
Last Updated
August 17, 2015
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Cornell University, Wake Forest University Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01658657
Brief Title
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Official Title
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
Cornell University, Wake Forest University Health Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Plasma Renin Activity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PRA-guided therapy
Arm Type
Experimental
Arm Description
Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
Arm Title
Fixed-dose combination treatment-guided therapy
Arm Type
Active Comparator
Arm Description
Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide
Intervention Type
Drug
Intervention Name(s)
Lisinopril
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Type
Drug
Intervention Name(s)
metoprolol
Intervention Type
Drug
Intervention Name(s)
lisinopril/hydrochlorothiazide
Intervention Description
This is a combination pill
Primary Outcome Measure Information:
Title
Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic
Description
At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (<140mmHG systolic and <90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg Not currently taking BP-lowering medication Clinician recommends pharmacologic treatment Willing to make necessary study visits Able to be contacted by phone Has a primary care clinician At least 18 years old Exclusion Criteria: Known secondary cause of hypertension Pregnancy Known diabetes, coronary artery disease or renal disease Known sulfonamide allergy or history of gout Participant's clinician recommends he/she not enroll Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg Resting heart rate < 55 beats per minute
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Viera, MD, MPH
Organizational Affiliation
Distinguished Associate Professor, Family Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
UNC Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

We'll reach out to this number within 24 hrs